To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Radiologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease.N Engl J Med. 1988; 318: 876-880
- Cocaine receptors labeled by [3H] 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.Mol Pharmacol. 1989; 36: 518-524
- [3H] CFT and [3H] LU 19–005: markers for cocaine receptor/dopamine nerve terminals in Parkinson's disease [abstract].Soc Neurosci Abstr. 1990; 16: 14
- Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum.Synapse. 1991; 9: 43-49
- Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.N Engl J Med. 1993; 328: 176-183
- Transplantation of fetal mesencephalic tissue in Parkinson's disease.N Engl J Med. 1995; 333: 730-731
- The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease.Neurosurgery. 1995; 36: 1118-1125
- Pallidotomy for Parkinson's disease.Neurosurg Clin N Am. 1995; 6: 105-112
- Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F] fluorodeoxyglucose method.Ann Neurol. 1984; 15: 419-424
- Technetium-99m HMPAO imaging in patients with basal ganglia disease.Br J Radiol. 1988; 61: 914-920
- The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.Arch Neurol. 1990; 47: 1290-1298
- Synthesis and purification of L-[18F] 6-fluorodopa.Appl Radiat Isot. 1988; 39: 1203-1206
- Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.J Cereb Blood Flow Metab. 1991; 11: 898-913
- Modeling of fluorine-18–6-fluoro-l-dopa in humans.J Nucl Med. 1996; 37: 432-437
- Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations.J Cereb Blood Flow Metab. 1985; 5: 584-590
- Nigrostriatal function in man studied with positron emission tomography.Ann Neurol. 1989; 26: 535-542
- Input functions for 6-[fluorine-18] fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.J Nucl Med. 1994; 35: 955-963
- Reproducibility and discriminating ability of fluorine-18–6-fluoro-l-dopa PET in Parkinson's disease.J Nucl Med. 1996; 37: 421-426
- Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET.J Neurol Neurosurg Psychiatry. 1998; 64: 314-319
- 6-[18F] fluoro-l-dopa metabolism in living human brain: a comparison of six analytical methods.J Cereb Blood Flow Metab. 1993; 13: 57-69
- Comparative analysis of striatal Fdopa uptake in Parkinson's disease: ratio method versus graphical analysis.J Nucl Med. 2002; 43: 1324-1330
- Human striatal l-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.J Cereb Blood Flow Metab. 1993; 13: 43-56
- Correlation of striatal fluorodopa uptake in the MPTP-monkey with dopaminergic indices.Ann Neurol. 1993; 34: 331-338
- Correlations in humans between premortem PET [18F] fluorodopa uptake, postmortem cell counts and striatal dopamine levels.Ann Neurol. 1993; 34: 324-330
- Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.Brain. 1996; 119: 2097-2103
- Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluorodopa.J Nucl Med. 1998; 38: 630-636
- Blinded positron emission tomography study of dopamine cell implantation in Parkinson's disease.Ann Neurol. 2001; 50: 181-187
- The effect of carbidopa administration on 6-[18F] fluoro-l-dopa kinetics in positron emission tomography.J Nucl Med. 1992; 33: 1472-1477
- The distribution and kinetics of [18F]6-fluoro-3-O-methyl-l-dopa in the human brain.J Cereb Blood Flow Metab. 1994; 14: 664-670
- Monoamine neuron innervation of the normal human brain: an 18F-dopa PET study.Brain Res. 2003; 982: 137-145
- Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.Can J Neurol Sci. 1984; 11: 174-179
- Striatal dopamine distribution in parkinsonian patients during life.J Neurol Sci. 1985; 69: 223-230
- Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.J Neurol Neurosurg Psychiatry. 1986; 49: 853-860
- Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.Ann Neurol. 1990; 28: 547-555
- In vivo study of dopa metabolism in Parkinson's disease.in: Fajn S. Jenner P. Marsden C.D. Teychenne P.F. Recent developments in Parkinson's disease. Raven Press, New York1986: 97-102
- Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.J Neurol Neurosurg Psychiatry. 1991; 54: 898-904
- Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration.Ann Neurol. 1989; 26: 766-770
- Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization.Ann Neurol. 1989; 26: 507-514
- Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations.J Neurol Sci. 1973; 20: 415-455
- Reproducibility of fluorine-18–6-fluorodopa positron emission tomography in normal human subjects.J Nucl Med. 1994; 35: 18-24
- Reproducibility and discriminating ability of fluorine-18–6-fluoro-l-dopa PET in Parkinson's disease.J Nucl Med. 1996; 37: 421-426
- Striatal function in normal aging: implications for Parkinson's disease.Ann Neurol. 1990; 28: 799-804
- Striatal 18F-dopa uptake: absence of an aging effect.J Cereb Blood Flow Metab. 1993; 13: 881-888
- Positron emission tomographic evidence for progression of human MPTP- induced dopaminergic lesions.Ann Neurol. 1994; 36: 765-770
- 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.Synapse. 2002; 43: 201-207
- An [18F] dopa PET and clinical study of the rate of progression of Parkinson's disease.Brain. 1996; 119: 585-591
- Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET.Neurol Neurosurg Psychiatry. 1998; 64: 314-319
- Rate of progression in Parkinson's disease: a [18F] fluoro-l-dopa pet study.mov disord. 2001; 16: 608-615
- Ageing and Parkinson's disease: substantia nigra regional selectivity.Brain. 1991; 114: 2283-2301
- The genetics of Parkinson's disease: a reconsideration.Neurology. 1990; 40: 7-16
- Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease.Nature. 1985; 317: 246-248
- The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred.Ann Neurol. 1992; 32: 609-617
- Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study.Ann Neurol. 1997; 41: 222-229
- Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.Brain. 2002; 125: 2248-2256
- Parkinson's disease in twins studied with 18F-dopa and positron emission tomography.Neurology. 1992; 42: 1894-1900
- Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors.Cell Transplant. 1997; 6: 309-315
- Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.Brain Res. 1999; 838: 51-59
- Dopamine agonists and neuroprotection in Parkinson's disease.Ann Neurol. 1998; 44: 167-174
- Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study.Ann Neurol. 2003; 54: 93-101
- Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopas on Parkinson disease progression.JAMA. 2002; 287: 1653-1661
- Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen.Ann Neurol. 1987; 22: 457-468
- Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease.Science. 1990; 247: 574-577
- Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease.N Engl J Med. 1992; 327: 1549-1555
- Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.brain. 1994; 117: 487-499
- Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.N Engl J Med. 1992; 327: 1541-1548
- Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).N Engl J Med. 1992; 327: 1556-1563
- Transplantation of embryonic dopamine neurons for severe Parkinson's disease.N Engl J Med. 2001; 344: 710-719
- Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease.Ann Neurol. 2001; 50: 181-187
- Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain.J Nucl Med. 1995; 36: 2298-2305
- Dopamine transporter imaging with fluorine-18-FPCIT and PET.J Nucl Med. 1998; 39: 1521-1530
- [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites.Synapse. 2001; 39: 332-342
- Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.Ann Neurol. 1996; 40: 873-884
- Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography.Ann Neurol. 1996; 40: 885-892
- In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.Ann Neurol. 2000; 47: 493-503
- Striatonigral degeneration: a clinicopathological study.Brain. 1990; 113: 1823-1842
- Accuracy of clinical diagnosis in parkinsonism: a prospective study.Can J Neurol Sci. 1991; 18: 275-278
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry. 1992; 55: 181-184
- Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.J Neurol Neurosurg Psychiatry. 1994; 57: 278-284
- Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration.Ann Neurol. 1989; 26: 239-247
- Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.Ann Neurol. 1984; 15: 419-424
- Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease.Neurology. 1985; 35: 1399-1405
- Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome: a [11C]diprenorphine PET study.Brain. 1995; 118: 951-958
- Progressive supranuclear palsy: clinico-pathological and biochemical studies.J Neural Transm Suppl. 1980; 16: 111-128
- [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.Eur J Pharmacol. 1984; 99: 167-175
- [3H]spiperone binding in the nigrostriatal system in human brain.Eur J Pharmacol. 1984; 99: 159-165
- Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.Ann Neurol. 1985; 18: 530-536
- Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography.Arch Neurol. 2001; 58: 1846-1851
- Subcortical dementia: frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.Brain. 1985; 108: 785-799
- Steele-Richardson-Olszewski syndrome: brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography.Brain. 1988; 111: 615-630
- Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography.Ann Neurol. 1988; 24: 399-406
- Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy.Ann Neurol. 1989; 25: 131-139
- Positron emission tomography study in progressive supranuclear palsy: brain hypometabolic pattern and clinicometabolic correlations.Arch Neurol. 1990; 47: 747-752
- Corticobasal degeneration: a unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography.Brain. 1991; 114: 541-556
- The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography.J Neurol Neurosurg Psychiatry. 1991; 54: 856-862
- PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration.J Neurol Sci. 1996; 139: 210-217
- Dopa-responsive dystonia: [18F]dopa positron emission tomography.Ann Neurol. 1991; 30: 24-30
- Positron emission tomography in manganese intoxication.Ann Neurol. 1989; 26: 647-651
- Patterns of local cerebral glucose utilization in Parkinson's disease and Huntington's disease.Ann Neurol. 1984; 15: 119-125
- Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.Mov Disord. 1986; 1: 69-77
- PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.Ann Neurol. 1986; 20: 296-303
- Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone.Acta Neurol Scand. 1987; 75: 87-94
- Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia.Ann Neurol. 1990; 27: 357-365
- A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.Ann Neurol. 1990; 28: 614-621
Article info
Identification
Copyright
© 2004 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
